BRAF and ganglioglioma: For instance, the presence of BRAF V600E mutations, particularly in gangliogliomas or astrocytomas, offers potential access to targeted inhibitors (e.g., vemurafenib, dabrafenib, and encorafenib), shifting paradigms for recurrent or unresectable disease.